Nabriva’s Xenleta Approved in Europe for Community-Acquired Pneumonia

The European Commission has approved Nabriva Therapeutics’ Xenleta for treatment of adults with community-acquired pneumonia when treatment with other antibacterial agents fails or is inappropriate. 

The approval was based on results from two phase 3 trials which determined Xenleta to be non-inferior to the standard-of-care, moxifloxacin, for treating adults with the community-acquired infection.

The FDA approved Xenleta for this indication in August 2019.